Belfast-based HealthTech startup SignaCor Therapeutics has €288k (£250k) in funding from VC agency Zinc as a way to advance the event of a brand new therapy designed to restore coronary heart injury and gradual the development of hypertrophic cardiomyopathy (HCM).
As we speak’s funding is a part of the successful package deal for being named the winner of Discovery Park’s startup development programme for improvements in cardiovascular well being. It’s going to type a part of a €1.1 million (£1 million) Seed spherical anticipated to shut in April.
Darach Neeson, CEO at SignaCor, says: “The Spark programme’s content material was distinctive – value-filled insights from UK life science business consultants and significant investor engagement. The teachings realized have influenced our technique, and we’d completely suggest it to different founders. We’re excited to now be a part of Zinc’s portfolio of modern life science corporations. This funding will permit us to execute our Part 2a trial plans and advance our regulatory technique, bringing us nearer to delivering a brand new therapy for sufferers with restricted therapy choices.”
Evaluation exhibits continued investor exercise throughout the cardiovascular innovation area, spanning therapeutics, diagnostics, and AI-driven cardiology instruments, offering context to SignaCor’s funding and goal.
In one of many largest rounds, NanoPhoria Bioscience, a Milan-based BioTech firm, secured €83.5 million in a Collection A to advance its lung-to-heart drug supply platform and progress a heart-failure therapeutic candidate into early scientific improvement. Within the UK, Oxford-based Ultromics raised €48 million in a Collection C to scale its AI-powered echocardiography platform designed to detect complicated types of coronary heart failure earlier, together with HFpEF and cardiac amyloidosis. In the meantime in France, Bordeaux-based DESKi secured €5.2 million in Seed funding to assist the worldwide rollout and improvement of its AI-driven cardiac imaging software program, HeartFocus.
Taken collectively, these bulletins characterize over €136 million in funding throughout the European cardiovascular innovation sector in 2025–2026. Though the businesses span totally different approaches – from therapeutics to imaging and diagnostic AI – the rounds illustrate continued funding curiosity in applied sciences addressing heart problems.
Inside this context, the €288k funding in Belfast-based SignaCor Therapeutics, a part of a €1.1 million Seed spherical, displays ongoing assist for early-stage corporations growing new therapies for coronary heart circumstances.
Programme Lead Renos Savva, Head of Innovation and Enterprise Growth at Discovery Park, provides: “SignaCor’s success is a testomony to what’s potential while you mix scientific rigour with the precise assist community. Discovery Spark is designed to bridge the hole between an incredible concept and a reputable enterprise, and seeing that translate into actual funding is enormously rewarding. The cardiovascular area is ripe for innovation, and we’re proud that Discovery Spark helps to drive it ahead.”
Based in 2024, SignaCor is a scientific stage, drug improvement firm, spun-out from Queen’s College Belfast, devoted to the therapy of cardiac illness.
They’re growing medicines for HCM, the place thickening of the guts muscle makes it more durable for blood to be pumped across the physique. In line with the corporate, this genetically inherited cardiac dysfunction impacts round 1 in 500 folks within the UK.
Led by CEO Darach Neeson and CSO Dr Chris Watson, SignaCor is engaged on a brand new first-in-class therapy to reverse coronary heart injury and forestall additional deterioration of coronary heart muscle mass.
SignaCor goals to handle the underlying illness pathology for the primary time, main to higher high quality of life and longer life expectations for sufferers.
Natalie Pankova, Companion, Well being and Life Science at Zinc, says: “Zinc’s partnership with Discovery Spark helped floor some actually thrilling corporations able to delivering significant advances for affected person impression, and we’re thrilled to have been capable of make this funding in SignaCor. Heart problems continues to characterize one of many biggest unmet challenges in international well being.
The corporate is pioneering a first-in-class therapeutic strategy to symptomatic HCM – one which goes past symptom administration to focus on the underlying illness pathology.
In line with the corporate, ‘Cardiaza’ is the primary and solely therapy that harnesses DNA methylation to handle a number of underlying causes of symptomatic HCM, together with established fibrosis, a key driver of illness development.
“What stood out about SignaCor was the power of the science mixed with a transparent, executable path to scientific impression. SignaCor’s progress and success by way of the programme demonstrates the ability of mixing science with the precise enterprise and ecosystem assist,” provides Natalie.
The funding was delivered by way of Discovery Spark, a enterprise development programme for founders working in life sciences, with specialist-led classes and mentoring unfold over seven weeks. A cohort of eight promising cardiovascular and cardiometabolic corporations took half, culminating in a pitch day with traders at Zinc’s London workplaces on the finish of 2025.
SignaCor was recognised as the general winner for his or her standout pitch presentation, skilled group and clear market want.
Because the fifth iteration of the Spark programme, the cohort’s concentrate on coronary heart well being was chosen for its excessive burden on lives, with cardiovascular ailments accounting for 1 in 4 of all deaths within the UK.
A sixth cohort of Discovery Spark is beginning in mid-March, with an open tech focus.
